Poland· PL-100206164

Valdoxan

A agomelatin product containing agomelatinum, registered in Poland by Les Laboratoires Servier. The same ATC class is registered in 13 of our 19 countries.

ATC N06AX22

Checked against URPL (Poland) on September 27, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about agomelatinumAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Agomelatin is registered in 13 of 19 countries.

Countries holding a registration under ATC N06AX22 (agomelatin), each read from that country’s own register.

This record: Poland, from URPL (Poland)
9 of them publish a price we can compare per daily dose

Search agomelatin products by name

Agomelatin · ATC N06AX22

13 / 19 countries

Belgiumprice
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
Switzerlandprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of agomelatin costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $0.72 in France to $1.72 in Switzerland — a ×2.4 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Agomelatin · price per daily dose (25 mg)

USD · FX 28 Sept 2026

CH Switzerland$1.72
FR France$0.72

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)

Active substance: Agomelatinum
Manufacturer: Les Laboratoires Servier
Country: Poland (PL)
ATC code: N06AX22
ATC class: Agomelatin
Defined daily dose: 25 mg, O
Reimbursed: Not published by this register
Source register: URPL (Poland)
Last checked: September 27, 2026

Packs & prices · 5

gtin
05909990686568
gtin
05909990686575
gtin
05909990686582
gtin
05909990932290
gtin
05909990935741

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for agomelatin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check agomelatin against other medicines How interaction checks work

Agomelatin · interactions on record

25 records

25 more interactions with mechanism and management, from a commercially licensed source.

Mechanism and what to do, in the interaction check

Interaction register. Grades as the source publishes them.

Same medicine, other countries

Agomelatin in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All agomelatin products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

Austria · Agogerolan, Agomelatin Genericon
Bulgaria · Агомелатин G.L. Pharma
Czechia · Agomelatin +pharma, Agomelatine G.L.Pharma
Germany · Agomaval, Agomelatin Abz
Denmark · Agomelatin Glenmark, Agomelatin Stada
Estonia · Lamegom
Spain · Agomelatina Aurovitas Spain, Agomelatina Qualigen
Finland · Agomelatine Stada, Agomelatine Viatris
France · Agomelatine Biogaran, Agomelatine Eg
United Kingdom (Northern Ireland) · Agomelatine Accord, Agomelatine Neuraxpharm
Hungary · Agomelatin Teva, Agomelatine Anpharm
Ireland · Agomelatine Viatris
Iceland · Agomelatine Stada, Valdoxan
Liechtenstein · Valdoxan
Lithuania · Agomelatine Anpharm, Lamegom
Malta · Agomaval
Netherlands · Agomaval, Agomelatine Accord
Norway · Valdoxan
Portugal · Agomelatina Ciclum, Agomelatina Generis
Sweden · Agomelatin Glenmark, Agomelatine Stada
Slovakia · Agomelatín Stada, Agomelatine G.L. Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/af7e26cc-1906-45e2-bf19-684e8b618148
GET /v1/drugs/af7e26cc-1906-45e2-bf19-684e8b618148?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "25 mg",
  "packaging": "05909990686568 ¦ Rp ¦ EU/1/08/499/003 ¦ 48856\n28 tabl.\n05909990686575 ¦ Rp ¦ EU/1/08/499/005 ¦ 48857\n56 tabl.\n05909990686582 ¦ Rp ¦ EU/1/08/499/008 ¦ 48858\n100 tabl.\n05909990932290 ¦ Rp ¦ EU/1/08/499/007 ¦ 72263\n98 tabl.\n05909990935741 ¦ Rp ¦ EU/1/08/499/006 ¦ 72588\n84 tabl.\nRp ¦ Skasowane ¦ EU/1/08/499/001 ¦ 115889\n7 tabl.\nRp ¦ EU/1/08/499/002 ¦ 115890\n14 tabl.\nRp ¦ Skasowane ¦ EU/1/08/499/004 ¦ 115891\n42 tabl.",
  "substance": "Agomelatinum 25 mg",
  "common_name": "Agomelatinum",
  "pl_product_id": "100206164",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

API reference MCP server Plans

See everything about agomelatin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console